JP2014503480A5 - - Google Patents

Download PDF

Info

Publication number
JP2014503480A5
JP2014503480A5 JP2013536727A JP2013536727A JP2014503480A5 JP 2014503480 A5 JP2014503480 A5 JP 2014503480A5 JP 2013536727 A JP2013536727 A JP 2013536727A JP 2013536727 A JP2013536727 A JP 2013536727A JP 2014503480 A5 JP2014503480 A5 JP 2014503480A5
Authority
JP
Japan
Prior art keywords
deuterium
rich
pharmaceutical composition
compound
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013536727A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014503480A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/057698 external-priority patent/WO2012058219A2/en
Publication of JP2014503480A publication Critical patent/JP2014503480A/ja
Publication of JP2014503480A5 publication Critical patent/JP2014503480A5/ja
Pending legal-status Critical Current

Links

JP2013536727A 2010-10-26 2011-10-25 ジュウテリウムリッチなラサギリン Pending JP2014503480A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40674010P 2010-10-26 2010-10-26
US61/406,740 2010-10-26
PCT/US2011/057698 WO2012058219A2 (en) 2010-10-26 2011-10-25 Deuterium enriched rasagiline

Publications (2)

Publication Number Publication Date
JP2014503480A JP2014503480A (ja) 2014-02-13
JP2014503480A5 true JP2014503480A5 (enExample) 2014-12-11

Family

ID=45973513

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013536727A Pending JP2014503480A (ja) 2010-10-26 2011-10-25 ジュウテリウムリッチなラサギリン

Country Status (17)

Country Link
US (2) US20120101168A1 (enExample)
EP (1) EP2632254A4 (enExample)
JP (1) JP2014503480A (enExample)
KR (1) KR20140023872A (enExample)
CN (1) CN103188933A (enExample)
AU (1) AU2011320611A1 (enExample)
BR (1) BR112013010308A2 (enExample)
CA (1) CA2816104A1 (enExample)
CL (1) CL2013001101A1 (enExample)
EA (1) EA201390613A1 (enExample)
IL (1) IL225852A0 (enExample)
MX (1) MX2013004598A (enExample)
NZ (1) NZ610526A (enExample)
PH (1) PH12013500821A1 (enExample)
SG (2) SG10201508771TA (enExample)
WO (1) WO2012058219A2 (enExample)
ZA (1) ZA201303505B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8809310B2 (en) * 2006-02-21 2014-08-19 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
AU2007235517B2 (en) 2006-04-03 2013-01-31 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Restless Legs Syndrome
AU2007334428B2 (en) * 2006-12-14 2014-05-29 Teva Pharmaceutical Industries, Ltd. Crystalline solid rasagiline base
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
EA201070842A1 (ru) * 2008-01-11 2011-04-29 Тева Фармасьютикал Индастриз, Лтд. Препаративные формы разагилина, их получение и применение
AU2009258120B2 (en) * 2008-06-10 2014-11-27 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
PT2451771E (pt) 2009-07-09 2014-09-19 Ratiopharm Gmbh Sais de rasagilina e suas preparações farmacêuticas
JP2013507352A (ja) * 2009-10-09 2013-03-04 テバ ファーマシューティカル インダストリーズ リミティド 進行性核上性麻痺の治療のためのラサギリンの使用
WO2011087791A1 (en) * 2009-12-22 2011-07-21 Teva Pharmaceutical Industries Ltd. 3-keto-n-propargyl-1-aminoindan
RU2587330C2 (ru) 2010-07-27 2016-06-20 Тева Фармасьютикал Индастриз Лтд. Применение разагилина для лечения обонятельной дисфункции
WO2012015946A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Dispersion of rasagiline citrate
CA2851433A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. R(+)-n-methyl-propargyl-aminoindan
BR112014008555A2 (pt) 2011-10-10 2017-04-18 Teva Pharma r(+)-n-formil-propargil-aminoindano
AR092168A1 (es) 2012-08-17 2015-03-25 Teva Pharma Formulaciones parenterales de rasagilina
CN120157593A (zh) * 2018-12-06 2025-06-17 内在生物技术有限公司 乙酰基-亮氨酸的氘代类似物
CN111323524B (zh) * 2020-04-08 2022-04-15 重庆华森制药股份有限公司 一种炔丙胺及其杂质的检测方法
CN115947675B (zh) * 2022-12-21 2024-05-31 博济医药科技股份有限公司 一种雷沙吉兰中间体及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
US20060018957A1 (en) * 2004-07-26 2006-01-26 Lerner E I Pharmaceutical dosage forms including rasagiline
ES2371883T3 (es) * 2004-11-24 2012-01-11 Teva Pharmaceutical Industries Ltd. Composiciones de rasagilina de disgregación oral.
EP1851188A1 (en) * 2005-02-22 2007-11-07 Teva Pharmaceutical Industries Limited Improved process for the synthesis of enantiomeric indanylamine derivatives
WO2007052274A2 (en) * 2005-11-06 2007-05-10 Brain Watch Ltd. Magnetic resonance imaging and spectroscopy means and methods thereof
AU2009254929B2 (en) * 2008-06-02 2014-03-13 Generics [Uk] Limited An improved process for the preparation of amines
EP2296462A4 (en) * 2008-06-13 2011-06-15 Teva Pharma RASAGILINE FOR INFLUENCING MORBUS PARKINSON
US20100172916A1 (en) * 2008-11-10 2010-07-08 Auspex Pharmaceuticals, Inc. Substituted hydroxyphenylamine compounds
US20100189790A1 (en) * 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
US20100286124A1 (en) * 2009-04-10 2010-11-11 Auspex Pharmaceuticals, Inc. Prop-2-yn-1-amine inhibitors of monoamine oxidase type b
US20120156139A1 (en) * 2009-08-31 2012-06-21 Rachel Katz-Brull Isotopically labeled neurochemical agents and uses therof for diagnosing conditions and disorders

Similar Documents

Publication Publication Date Title
JP5373405B2 (ja) 選択的アンドロゲン受容体モジュレーター
EP2912047B1 (en) Antiviral phosphonate analogues and process for preparation thereof
IL255433B2 (en) (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
JP5468608B2 (ja) 4−オキソ−オクタヒドロ−インドール−1−カルボサイリックアシッドメチルエステルとその誘導体の調製方法
JP2020520946A5 (enExample)
EP4293009A2 (en) Fenfluramine compositions and methods of preparing the same
WO2019177975A1 (en) Antibiotics effective for gram-negative pathogens
JP2009542613A5 (enExample)
CN103188933A (zh) 富集氘的雷沙吉兰
JP2014510746A5 (enExample)
TW201420586A (zh) 抗病毒化合物之固體形式
JP2007522162A5 (enExample)
JP5955364B2 (ja) 中間体として有用な新規化合物
JP2018510189A5 (enExample)
KR20170002433A (ko) 의약으로 사용하기 위한 펄린돌 광학이성질체의 약학적으로 허용가능한 염
JP6522094B2 (ja) 4−[2−ジメチルアミノ−1−(1−ヒドロキシシクロヘキシル)エチル]フェニル4−メチルベンゾエートヒドロクロリドの多形体、それらを作製する方法及びそれらの使用
CN108210933B (zh) 一种地佐辛与聚乙二醇的结合物
CN111909174A (zh) 吡啶酮衍生物的晶型及制备方法和应用
CN103764608B (zh) 用于治疗炎性肠病的茚衍生物
JPS60116678A (ja) n‐プロパノールアミン誘導体エーテル
JP5863846B2 (ja) イリノテカンの製造方法
TW202608850A (zh) 降冰片烷衍生物及其藥物用途
TW202345839A (zh) 用於製造3,6-二取代-咪唑并[1,2-b]嗒𠯤化合物之方法
CN102633852A (zh) 亚胺类豆甾醇衍生物及其在抗癌药物中的应用
CN114286811A (zh) 富马酸单甲酯的前药